预约演示

更新于：2025-05-07

FGF13 x FGF11

更新于：2025-05-07

基本信息

关联

项与 FGF13 x FGF11 相关的药物

HG-1031

靶点

FGF11 x FGF13

作用机制

FGF11 modulators [+1]

在研机构-

原研机构

Human Genome Sciences, Inc.

在研适应症-

非在研适应症

神经系统疾病

最高研发阶段无进展

首次获批国家/地区-

首次获批日期1800-01-20

100 项与 FGF13 x FGF11 相关的临床结果

登录后查看更多信息

100 项与 FGF13 x FGF11 相关的转化医学

登录后查看更多信息

0 项与 FGF13 x FGF11 相关的专利（医药）

登录后查看更多信息

项与 FGF13 x FGF11 相关的文献（医药）

2025-07-01·Journal of Biotechnology

Production and purification of recombinant long protein isoforms of FGF11 subfamily

Article

作者: Krowarsch, Daniel ; Opalinski, Lukasz ; Sochacka, Martyna ; Sidor, Szymon ; Zakrzewska, Malgorzata ; Biadun, Martyna ; Kalka, Marta ; Karelus, Radoslaw

The FGF11 subfamily of FGF proteins also known as fibroblast growth factor homologous factors (FHFs) includes four proteins, FGF11, FGF12, FGF13, and FGF14. They are mainly expressed in excitable cells but are also present in fibroblasts or osteoclasts, where their function is much less understood. Each FGF11-14 protein has at least two isoforms formed by alternative splicing, which differ in both cellular localization and function. Until recently, only the short isoforms had been efficiently produced and purified in recombinant form. Here, we developed a protocol to produce in the bacterial expression system and efficiently purify the long "a" isoforms of FGF11, FGF12, FGF13 and FGF14. In addition, we characterized their biophysical and biological properties, demonstrating that they activate downstream signaling and, unlike short "b" isoforms, induce cell proliferation.

2024-11-01·Differentiation

Fibroblast Growth Factor (FGF) 13

Review

作者: Uribe, Rosa A ; Uribe, Rosa A. ; Rivas, Lucia J. ; Rivas, Lucia J

Fibroblast Growth Factor (FGF) 13, also referred to as FGF homologous factor (FHF) 2, is a member of the FGF11 subfamily that is characterized as having sequence similarities to classical FGF receptor (FGFR)-binding FGFs, but functionally do not bind FGFRs. In this primer mini-review, we summarize current knowledge regarding FGF13 expression, mutant analyses, and gene and protein structure. Similar to other FHFs, FGF13 has been considered a non-secreted protein that lacks an amino signal and is prominently expressed in developing and mature neurons of the central and peripheral nervous systems, as well as the heart. The expression of FGF13 is not limited to early embryonic stages and has been shown to persist in adult tissues. As well, FGF13 is known to localize subcellularly, both within the cytoplasm and the nucleus. FGF13 is extremely adaptable, as it interacts with MAPK scaffolding protein islet brain 2 (IB2), stabilizes microtubules, or binds to voltage-gated sodium channels. Fgf13 mutant mouse lines display various neurological pathologies. Through sequence mapping, FGF13 is considered a candidate causative gene that is mutated in multiple human X-linked neurological diseases.

2023-12-01·Environmental Research

Identification of antisense and sense RNAs of intracrine fibroblast growth factor components as novel biomarkers in colorectal cancer and in silico studies for drug and nanodrug repurposing

Article

作者: Maghsoudloo, Mazaher ; Entezari, Maliheh ; Taheriazam, Afshin ; Zali, Mohammad Reza ; Nazemalhosseini-Mojarad, Ehsan ; Khanabadi, Binazir ; Asadzadeh Aghdaei, Hamid ; Hushmandi, Kiavash ; Valle, Laura ; Rejali, Leili ; Mohammadpoor, Hadis ; Hashemi, Mehrdad

INTRODUCTIONColorectal cancer (CRC) is one of the most malignant tumors and in which various efforts for screening is inconclusive.The intracrine FGF panel, the non-tyrosine kinase receptors (NTKR) FGFs and affiliated antisenses play a pivotal role in FGF signaling.The expression levels of coding and non-coding intracrine FGFs were assessed in CRC donors.Also, substantial costs and slow pace of drug discovery give high attraction to repurpose of previously discovered drugs to new opportunities.OBJECTIVESThe aim of present study was to evaluate the potential role of the coding and non-coding intracrine FGFs as a new biomarkers for CRC cases and defining drug repurposing to alleviate FGF down regulation.METHODSRNA-seq data of colon adenocarcinomas (COAD) was downloaded using TCGA biolinks package in R.The DrugBank database (https://go.drugbank.com/) was used to extract interactions between drugs and candidate genes. A total of 200 CRC patients with detailed criteria were enrolled.RNAs were extracted with TRIzol-based protocol and amplified via LightCycler® instrument.FGF11 and FGF13 proteins validation was performed by used of immunohistochemistry technique in tumor and non-tumoral samples.Pearson's correlation analysis and ROC curve plotted by Prism 8.0 software.RESULTSRNA-seq data from TCGA was analyzed by normalizing with edgeR.Differentially expressed gene (DEG) analysis was generated. WCC algorithm extracted the most significant genes with a total of 47 genes. Expression elevation of iFGF antisenses (12AS,13As,14AS) compared with the normal colon tissue were observed (P = 0.0003,P = 0.042,P = 0.026, respectively). Moreover,a significant decrease in expression of the corresponding sense iFGF genes was detected (P < 0.0001).Plotted receiver operating characteristic (ROC) curves for iFGF components' expression showed an area of over 0.70 (FGF11-13: 0.71% and FGF12-14: 0.78%, P < 0.001) for sense mRNA expression, with the highest sensitivity for FGF12 (92.8%) and lowest for FGF11 (61.41%).The artificial intelligence (AI) revealed the valproic acid as a repurposing drug to relief the down regulation of FGF12 and 13 in CRC patients.CONCLUSIONIntracrine FGFs panel was down regulated versus up regulation of dependent antisenses. Thus, developing novel biomarkers based on iFGF can be considered as a promising strategy for CRC screening.In advanced, valporic acid detected by AI as a repurposing drug which may be applied in clinical trials for CRC treatment.

分析

对领域进行一次全面的分析。

或

查看完整样例数据

Eureka LS:

全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步

立即开始免费试用!

智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。

立即开始数据试用!

智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。